Alivus Life Sciences Ltd vs Phaarmasia Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 27.2 on March 2025 . This represents a CAGR of 19.36% over 4 yearsThe P/E Ratio of Phaarmasia Ltd changed from 54 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 13229 crore on March 2025 . This represents a CAGR of 23.84% over 4 yearsThe Market Cap of Phaarmasia Ltd changed from ₹ 16.97 crore on March 2021 to ₹ 20.02 crore on March 2025 . This represents a CAGR of 3.36% over 5 years The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 686.82 crore as compare to the Sep '25 revenue of ₹ 602.7 crore. This represent the growth of 13.96% The revenue of Phaarmasia Ltd for the Dec '25 is ₹ 35.21 crore as compare to the Sep '25 revenue of ₹ 16.69 crore. This represent the growth of 110.96% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 219.54 crore as compare to the Sep '25 ebitda of ₹ 193.89 crore. This represent the growth of 13.23% The ebitda of Phaarmasia Ltd for the Dec '25 is ₹ 19.99 crore as compare to the Sep '25 ebitda of ₹ 1.75 crore. This represent the growth of 1042% The net profit of Alivus Life Sciences Ltd changed from ₹ 111.48 crore to ₹ 150.26 crore over 7 quarters. This represents a CAGR of 18.60% The net profit of Phaarmasia Ltd changed from ₹ 0.28 crore to ₹ 16.27 crore over 7 quarters. This represents a CAGR of 918.90% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Phaarmasia Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Phaarmasia Ltd

Incorporated in 1981, Phaarmasia Limited (unit-I) is the part of the Maneesh Pharmaceutical Limited, with its headquarters and marketing office in Mumbai.
M/s Phaarmasia Limited Unit-II was established in 1993-94.
The Company is engaged in manufacturing and marketing of Oral contraceptive tablets' with various therapeutic dosage combinations along with iron tablets for Ministry of Health & Family Welfare and for Exports. The plant is situated in a hygienic environment; free from dust, smoke, chemical & biological emission.
Phaarmasia Ltd. Is an independent State-of-the-art-manufacturing unit having manufacturing facility of international standards with manufacturing capacity of more than 30 million units per annum. During the year 2000, the company became a Sick Industrial Company under SICA and therefore the same was referred to the BIFR.

FAQs for the comparison of Alivus Life Sciences Ltd and Phaarmasia Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Phaarmasia Ltd?

Market cap of Alivus Life Sciences Ltd is 13,106 Cr while Market cap of Phaarmasia Ltd is 67 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Phaarmasia Ltd?

The stock performance of Alivus Life Sciences Ltd and Phaarmasia Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Phaarmasia Ltd?

As of May 5, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1067.85. On the other hand, Phaarmasia Ltd stock price is INR ₹98.16.

How do dividend payouts of Alivus Life Sciences Ltd and Phaarmasia Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Phaarmasia Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.